[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL105693A0 - Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents - Google Patents

Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents

Info

Publication number
IL105693A0
IL105693A0 IL105693A IL10569393A IL105693A0 IL 105693 A0 IL105693 A0 IL 105693A0 IL 105693 A IL105693 A IL 105693A IL 10569393 A IL10569393 A IL 10569393A IL 105693 A0 IL105693 A0 IL 105693A0
Authority
IL
Israel
Prior art keywords
atherosclerosis
azepino
pyridino
pyrrolidino
substituted oximes
Prior art date
Application number
IL105693A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL105693A0 publication Critical patent/IL105693A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL105693A 1992-06-17 1993-05-13 Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents IL105693A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90022992A 1992-06-17 1992-06-17

Publications (1)

Publication Number Publication Date
IL105693A0 true IL105693A0 (en) 1993-09-22

Family

ID=25412199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105693A IL105693A0 (en) 1992-06-17 1993-05-13 Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents

Country Status (13)

Country Link
US (3) US5565468A (xx)
EP (1) EP0649425B1 (xx)
JP (1) JPH07507796A (xx)
CN (1) CN1081678A (xx)
AT (1) ATE177426T1 (xx)
AU (1) AU4293393A (xx)
DE (1) DE69323883T2 (xx)
DK (1) DK0649425T3 (xx)
ES (1) ES2130269T3 (xx)
GR (1) GR3029946T3 (xx)
IL (1) IL105693A0 (xx)
MX (1) MX9303594A (xx)
WO (1) WO1993025553A1 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
HUP0401292A3 (en) * 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
US7087626B2 (en) * 2001-05-24 2006-08-08 Eli Lilly And Company Pyrrole derivatives as pharmaceutical agents
CA2494574C (en) * 2002-10-22 2011-05-17 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
WO2007008529A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
AU2008273050A1 (en) * 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-a]pyridines and their use in cancer therapy
NZ588376A (en) * 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
CN103980281B (zh) * 2014-05-27 2016-06-08 天津市斯芬克司药物研发有限公司 一种咪唑吡嗪化合物及其制备方法
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
KR102659373B1 (ko) 2015-04-03 2024-04-23 인사이트 홀딩스 코포레이션 Lsd1 저해제로서 헤테로사이클릭 화합물
EP3334709A1 (en) 2015-08-12 2018-06-20 Incyte Corporation Salts of an lsd1 inhibitor
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600969A (en) * 1977-01-07 1981-10-21 Acf Chemiefarma Nv Heterocyclic compounds
US4352804A (en) * 1978-07-25 1982-10-05 Acf Chemiefarma Nv Oxime ethers, their preparation and pharmaceutical compositions containing them
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
EP0649425B1 (en) 1999-03-10
DE69323883T2 (de) 1999-07-22
ES2130269T3 (es) 1999-07-01
ATE177426T1 (de) 1999-03-15
US5523318A (en) 1996-06-04
DK0649425T3 (da) 1999-09-27
WO1993025553A1 (en) 1993-12-23
DE69323883D1 (de) 1999-04-15
MX9303594A (es) 1994-01-31
GR3029946T3 (en) 1999-07-30
US5565468A (en) 1996-10-15
AU4293393A (en) 1994-01-04
EP0649425A1 (en) 1995-04-26
CN1081678A (zh) 1994-02-09
US5597816A (en) 1997-01-28
JPH07507796A (ja) 1995-08-31

Similar Documents

Publication Publication Date Title
IL105693A0 (en) Pyridino-,pyrrolidino-and azepino-substituted oximes useful as anti-atherosclerosis and antihypercholesterolemic agents
HU0004863D0 (xx)
AP9300598A0 (en) Compositions and method for waste treatment
ZA9333B (en) Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone
BG103170A (en) Polymorphic form ii of finasteride and method for its preparation
AU4598796A (en) Improved method for the treatment and stabilization of hazardous waste
GB9310659D0 (en) Culturing of micro-organisms
AU4520893A (en) Sterilization process and composition
GR3020689T3 (en) Pyrrole derivatives
AU5159493A (en) Hazardous waste transportation and disposal
AU5271593A (en) Apparatus and methods for the utilization of combustible materials especially of industrial and household waste
AU657439B2 (en) Enhancer for the antianemia effect of erythropoietin and method of augmenting the antianemia effect of erythropoietin
BG100248A (en) Squalene synthetase inhibitors
AU7122891A (en) Oxetanones
AU4532893A (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
GR3026134T3 (en) 4-hydroxy-phenyl-beta-d-glucose monoesters, their method of preparation and their use in the cosmetic, dental-care, pharmaceuticals and food stuff fields.
AU3162093A (en) Process for processing and destroying domestic and/or industrial waste and fuel produced from such waste
FR2709114B1 (fr) Armoire de tri pour recyclage des déchets.
AU5538794A (en) Biologically active compounds and process therefor
AU1414995A (en) Residue and waste treatment process
HK72597A (en) Elimination of scanning disturbances
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
PL312966A1 (en) Derivatives of thiocarbamoil
AP9600790A0 (en) Process for preparation of substituted steroidal dienes and novel intermediates used in said process.
AU8497191A (en) Compositions and methods for treating hiv infections